Navigation Links
Codexis Names Lori Giver VP Systems Biology
Date:3/31/2009

REDWOOD CITY, Calif., March 31 /PRNewswire/ -- Codexis, Inc. today announced Lori Giver, Ph.D., has been named to the new position of Vice President, Systems Biology for Codexis Bioindustrials. She is responsible for cellular engineering, molecular biology, and computational biology. Dr. Giver reports to David Anton, Ph.D., Vice President, Bioindustrials Research and Development.

Dr. Giver is a widely-respected researcher in the directed evolution of genes and proteins. She joined Codexis in 2002 from Maxygen, where she was responsible for biocatalyst discovery and development. At Codexis, she has held a series of scientific leadership roles ranging from Associate Director, Research & Development to her most recent position as Senior Director, Evolution Technology.

She received a bachelor's degree in molecular and cell biology from the University of California at Berkeley, and a Ph.D. in molecular, cell and developmental biology from Indiana University, Bloomington, where she focused on the directed evolution of nucleic acids with Dr. Andrew Ellington. Dr. Giver did post-doctoral research in directed evolution of proteins at the California Institute of Technology with advisor Dr. Frances Arnold, a pioneer in the field of directed evolution and biocatalysis.

"Lori Giver's contribution to the development of today's strong and broad Codexis technology platform has been invaluable," Dr. Anton said. "She is one of the original core team of scientists that built both our expertise in biocatalysis and our world-class reputation in this field. Her appointment recognizes the role that systems biology, in combination with biocatalysis, will play in finding solutions to the critical need for renewable fuels and future clean technology products. Lori's advancement to our senior scientific leadership team recognizes her strong personal and professional dedication to our company, to her colleagues, and to finding technology solutions to the major challenges facing our society."

Codexis, Inc. is a clean technology company. The company develops industrial biocatalysts, including enzymes and microbes. Codexis technology is used in the energy industry to enable next generation, non-food biofuels and by global pharmaceutical companies for cost-effective manufacturing of human therapeutics. Future commercial applications include carbon management, water treatment and chemical manufacturing. For more information, visit www.codexis.com.

Contact: Lyn Christenson, lyn.christenson@codexis.com, 650-421-8144 or Saskia Sidenfaden, ssidenfaden@mww.com, 212-827-3771.


'/>"/>
SOURCE Codexis, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Codexis, Teva in Licensing Agreement Final
2. Codexis Names Vice President, Intellectual Property
3. Codexis, Arch Announce Expanded Collaboration
4. Codexis, Inc. Files Registration Statement for Proposed Initial Public Offering
5. Codexis Names David Anton VP Bioindustrials R&D
6. Codexis Launches Codex(TM) MicroCyp Platform to Produce Drug Metabolites and Novel Lead Compounds
7. Rothwell, Wolf Elected to Codexis Board
8. Codexis Opens Singapore Laboratory
9. Bruce Pasternack Elected to Codexis Board
10. Codexis Licenses New Drug Metabolite Profiling and Lead Diversification Technology From the California Institute of Technology
11. Codexis Appoints Singapore Laboratories Managing Director
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- Houston Methodist Willowbrook Hospital has signed a ... serve as their official health care provider. As ... provide sponsorship support, athletic training services, and most ... athletes and families. "We are excited ... to bring Houston Methodist quality services and programs ...
(Date:6/23/2016)...   EpiBiome , a precision microbiome engineering company, ... financing from Silicon Valley Bank (SVB). The financing will ... its drug development efforts, as well as purchase additional ... has been an incredible strategic partner to us – ... would provide," said Dr. Aeron Tynes Hammack , ...
(Date:6/23/2016)... LOUISVILLE, Ky. , June 23, 2016 /PRNewswire/ ... from two Phase 1 clinical trials of its ... double-blind, placebo-controlled, single and multiple ascending dose studies ... and pharmacodynamics (PD) of subcutaneous injection in healthy ... APL-2 subcutaneously (SC) either as a single dose ...
(Date:6/23/2016)... ... June 23, 2016 , ... ClinCapture, the only free ... and will showcase its product’s latest features from June 26 to June 30, ... poster on Disrupting Clinical Trials in The Cloud during the conference. DIA ...
Breaking Biology Technology:
(Date:5/12/2016)... WearablesResearch.com , a brand of Troubadour ... from the Q1 wave of its quarterly wearables survey. ... receptivity to a program where they would receive discounts ... company. "We were surprised to see that ... LaColla , CEO of Troubadour Research, "primarily because there ...
(Date:4/26/2016)... LONDON , April 26, 2016 /PRNewswire/ ... Systems, a product subsidiary of Infosys (NYSE: ... partnership to integrate the Onegini mobile security platform ... http://photos.prnewswire.com/prnh/20151104/283829LOGO ) The integration ... security to access and transact across channels. Using ...
(Date:4/14/2016)... , April 14, 2016 ... Malware Detection, today announced the appointment of Eyal ... new role. Goldwerger,s leadership appointment comes at ... heels of the deployment of its platform at several ... biometric technology, which discerns unique cognitive and physiological factors, ...
Breaking Biology News(10 mins):